



|                |                   |
|----------------|-------------------|
| Document No.   | 1175-0001 Rev. 03 |
| Effective Date | 14 Jul 2025       |
| Page No.       | 1 of 7            |

|                 |                             |
|-----------------|-----------------------------|
| Document Title: | TUDRIQEV™ Safety Data Sheet |
|-----------------|-----------------------------|

## SECTION I - IDENTIFICATION

|                    |                                                                  |
|--------------------|------------------------------------------------------------------|
| NAME:              | TUDRIQEV™                                                        |
| SYNONYMS:          | vusolimogene oderparepvec; vusolimogene oderparepvec-wtpg; RP1   |
| ACTIVE INGREDIENT: | rHSV-1hGM-CSF/GALV-GP-R <sup>-</sup>                             |
| CAS #:             | 2305659-09-8                                                     |
| MANUFACTURED BY:   | Replimune, Inc<br>33 New York Ave<br>Framingham, MA 01701<br>USA |

**PRODUCT INFORMATION & EMERGENCY TELEPHONE NUMBER** +1-877-375-0095 (USA)

### DESCRIPTION:

TUDRIQEV (vusolimogene oderparepvec) is a fusion-enhanced herpes simplex virus, type 1 (HSV-1) oncolytic immunotherapy that is administered intratumorally. TUDRIQEV encodes a fusogenic glycoprotein derived from gibbon ape leukemia virus with the R sequence deleted (GALV-GP-R<sup>-</sup>) and human granulocyte-macrophage colony-stimulating factor (GM-CSF). TUDRIQEV is a non-pathogenic version of HSV-1 with the neurovirulence factor ICP34.5 deleted so that replication occurs selectively in tumors and not in healthy tissue.

## SECTION II – HAZARD IDENTIFICATION

|                          |                                                                                                                                                                                                                    |
|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Classification:          | This product is not considered hazardous under the Hazard Communication Standard as defined in 29 CFR 1910.1200 Sections (c) & (d).                                                                                |
| Hazard Pictograms:       | None                                                                                                                                                                                                               |
| Signal word:             | None                                                                                                                                                                                                               |
| Hazard statements:       | None                                                                                                                                                                                                               |
| Precautionary statement: | Use standard precautions (inclusive of inclusive of universal precautions) with proper personal protective equipment, proper engineering controls and use within the parameters of the purchaser's safety program. |
| Unknown acute toxicity:  | None                                                                                                                                                                                                               |

Replimune documentation is considered proprietary and is made available for business operations and review by employees of Replimune and regulatory agencies. Distribution to third parties without written permission is prohibited.



|                       |                   |
|-----------------------|-------------------|
| <b>Document No.</b>   | 1175-0001 Rev. 03 |
| <b>Effective Date</b> | 14 Jul 2025       |
| <b>Page No.</b>       | 2 of 7            |

|                        |                             |
|------------------------|-----------------------------|
| <b>Document Title:</b> | TUDRIQEV™ Safety Data Sheet |
|------------------------|-----------------------------|

### SECTION III – COMPOSITION/INFORMATON ON INGREDIENTS

| Component Name                        | CAS Number   | Concentration              | Classification            |
|---------------------------------------|--------------|----------------------------|---------------------------|
| rHSV-1hGM-CSF/GALV-GP-R-              | 2305659-09-8 | 1 x 10 <sup>6</sup> PFU/mL | Not a hazardous substance |
| rHSV-1hGM-CSF/GALV-GP-R-              | 2305659-09-8 | 1 x 10 <sup>7</sup> PFU/mL | Not a hazardous substance |
| disodium hydrogen phosphate dihydrate | 10028-24-7   | <b>7.0 mg/mL</b>           | Not a hazardous substance |
| Sodium dihydrogen phosphate dihydrate | 13472-35-0   | <b>1.4 mg/mL</b>           | Not a hazardous substance |
| sodium chloride                       | 7647-14-5    | <b>1.3 mg/mL</b>           | Not a hazardous substance |
| myo-inositol                          | 87-89-8      | <b>39.0 mg/mL</b>          | Not a hazardous substance |
| d-sorbitol                            | 50-70-4      | <b>19.5 mg/mL</b>          | Not a hazardous substance |
| human serum albumin                   | 70024-90-7   | <b>5.1 mg/mL</b>           | Not a hazardous substance |

### SECTION IV – FIRST AID MEASURES

#### FIRST AID/TREATMENT:

|                                                              |                                                                                                                             |
|--------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| <b>In case of inhalation:</b>                                | Move to fresh air                                                                                                           |
| <b>In case of skin contact:</b>                              | Remove contaminated clothing and rinse skin with water, followed by washing with soap and water.                            |
| <b>In case of contact with eyes or mucous membranes:</b>     | Remove contact lenses. Flush with clean water for at least 15 minutes.                                                      |
| <b>In case of exposure to broken skin or a needle stick:</b> | Thoroughly clean the site with soap and water or use a disinfectant. See a physician for monitoring for signs of infection. |
| <b>In case of ingestion:</b>                                 | Do not induce vomiting. Rinse mouth with water. Get medical attention if symptoms occur.                                    |

Replimune documentation is considered proprietary and is made available for business operations and review by employees of Replimune and regulatory agencies. Distribution to third parties without written permission is prohibited.



|                       |                   |
|-----------------------|-------------------|
| <b>Document No.</b>   | 1175-0001 Rev. 03 |
| <b>Effective Date</b> | 14 Jul 2025       |
| <b>Page No.</b>       | 3 of 7            |

|                        |                             |
|------------------------|-----------------------------|
| <b>Document Title:</b> | TUDRIQEV™ Safety Data Sheet |
|------------------------|-----------------------------|

**Notes to physician:** TUDRIQEV is sensitive to the antiviral agents such as the thymidine kinase inhibitor acyclovir.

## SECTION V – FIRE AND EXPLOSION MEASURES

**Extinguishing media:** Use an extinguishing agent suitable for the surrounding area.

**Specific hazards arising from the chemical:** Thermal decomposition can lead to release of irritating gases and vapors. Keep product and empty container away from heat and sources of ignition.

**Protective equipment and precautions for firefighters:** As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective gear.

## SECTION VI – ACCIDENTAL RELEASE MEASURES

**Personal precautions, protective equipment and emergency procedures:** Use personal protective equipment and appropriate laboratory procedures.

**Methods and material for containment and cleaning up:** Allow aerosols to settle; wearing protective clothing, gently cover spill with paper towel or lint-free wipe.  
Apply either 70% isopropanol or Decon90 (5%) and allow to sit for 30 seconds to ensure decontamination.  
Allow sufficient contact time for absorption before removing towel or wipe.  
Materials used for cleaning should be disposed of as biohazardous waste.

**Environmental precautions:** Although HSV-1 does not persist in natural ecosystems, avoid release of TUDRIQEV into the environment.

## SECTION VII – HANDLING AND STORAGE

**Precautions for safe handling:** Handle in accordance with Biosafety Level 1 procedures. Standard precautions are recommended for healthcare facilities preparing and administering the product with single dose vials.  
When working with volumes greater than 10L (eg, manufacturing) use of Biosafety Level 2 practices is recommended for work tasks.

**Storage conditions:** Protect TUDRIQEV from light. Store vials in the original carton until use.

**Storage:** Store at -70°C to -90°C (-94°F to -130°F).  
Once thawed:

Replimune documentation is considered proprietary and is made available for business operations and review by employees of Replimune and regulatory agencies. Distribution to third parties without written permission is prohibited.



|                       |                   |
|-----------------------|-------------------|
| <b>Document No.</b>   | 1175-0001 Rev. 03 |
| <b>Effective Date</b> | 14 Jul 2025       |
| <b>Page No.</b>       | 4 of 7            |

|                        |                             |
|------------------------|-----------------------------|
| <b>Document Title:</b> | TUDRIQEV™ Safety Data Sheet |
|------------------------|-----------------------------|

- TUDRIQEV 10<sup>6</sup> PFU/mL vial may be stored at 2°C to 8°C (36°F to 46°F) for up to 2 days
- TUDRIQEV 10<sup>7</sup> PFU/mL vial may be stored at 2°C to 8°C (36°F to 46°F) for up to 10 days.
- Do not refreeze.

## SECTION VIII – EXPOSURE CONTROLS/PERSONAL PROTECTION

|                                       |                                                                                                                                               |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Exposure guidelines:</b>           | This product does not contain any hazardous materials with occupational exposure limits established by the region-specific regulatory bodies. |
| <b>Engineering controls:</b>          | Use standard precautions (inclusive of universal precautions). Maintain adequate ventilation.                                                 |
| <b>Personal protective equipment:</b> | Use laboratory coat, protective gloves, safety glasses and suitable protective clothing.                                                      |

## SECTION IX – PHYSICAL AND CHEMICAL PROPERTIES

|                                                      |                                   |
|------------------------------------------------------|-----------------------------------|
| <b>Physical state:</b>                               | Liquid at room temperature        |
| <b>Appearance/color:</b>                             | Translucent to opaque, colorless  |
| <b>Odor/odor threshold:</b>                          | No Data Available.                |
| <b>Melting point:</b>                                | -2.4 °C                           |
| <b>Freezing point:</b>                               | -16.3 °C                          |
| <b>Boiling point:</b>                                | No Data Available.                |
| <b>Flash point:</b>                                  | No Data Available.                |
| <b>Flammability:</b>                                 | No Data Available.                |
| <b>Upper/lower flammability or explosive limits:</b> | No Data Available.                |
| <b>Auto-ignition temperature:</b>                    | No Data Available.                |
| <b>Decomposition temperature:</b>                    | No Data Available.                |
| <b>pH:</b>                                           | 7.2 to 7.5                        |
| <b>Viscosity:</b>                                    | 1.2 (based on formulation buffer) |
| <b>Solubility(ies):</b>                              | No Data Available.                |
| <b>Partition coefficient:</b>                        | No Data Available.                |
| <b>Vapor pressure/evaporation rate:</b>              | No Data Available.                |
| <b>Vapor density:</b>                                | No Data Available.                |
| <b>Relative density:</b>                             | 1.03 g/mL                         |

Replimune documentation is considered proprietary and is made available for business operations and review by employees of Replimune and regulatory agencies. Distribution to third parties without written permission is prohibited.



|                       |                   |
|-----------------------|-------------------|
| <b>Document No.</b>   | 1175-0001 Rev. 03 |
| <b>Effective Date</b> | 14 Jul 2025       |
| <b>Page No.</b>       | 5 of 7            |

|                        |                             |
|------------------------|-----------------------------|
| <b>Document Title:</b> | TUDRIQEV™ Safety Data Sheet |
|------------------------|-----------------------------|

**Particle characteristics**

Subvisible

**Other information:**

May settle. Swirl gently before use.

## SECTION X – STABILITY AND REACTIVITY

|                                            |                                                                                                      |
|--------------------------------------------|------------------------------------------------------------------------------------------------------|
| <b>Reactivity:</b>                         | No data available.                                                                                   |
| <b>Chemical stability:</b>                 | The product is stable.                                                                               |
| <b>Possibility of hazardous reactions:</b> | Under normal conditions of storage and use, hazardous reactions will not occur.                      |
| <b>Conditions to avoid:</b>                | No data available.                                                                                   |
| <b>Incompatible materials:</b>             | No data available.                                                                                   |
| <b>Hazardous decomposition products:</b>   | Under normal conditions of storage and use, hazardous decomposition products should not be produced. |

## SECTION XI – TOXICOLOGICAL INFORMATION

### Acute toxicity:

| <b>Component:</b>                     | <b>LD50 Oral</b>         | <b>LD50 Dermal</b>          | <b>LC50 Inhalation</b>     |
|---------------------------------------|--------------------------|-----------------------------|----------------------------|
| rHSV-1hGM-CSF/GALV                    | Not listed               | Not listed                  | Not listed                 |
| disodium hydrogen phosphate dihydrate | LD50 = 17 g/kg (Rat)     | Not listed                  | Not listed                 |
| Sodium dihydrogen phosphate dihydrate | LD50 = 8290 mg/kg (Rat)  | LD50 > 7940 mg/kg (Rabbit)  | LC50 > 0.83 mg/L (Rat) 4 h |
| sodium chloride                       | LD50 = 3 g/kg (Rat)      | LD50 > 10000 mg/kg (Rabbit) | LC50 > 42 mg/L (Rat) 1 h   |
| myo-inositol                          | Not listed               | Not listed                  | Not listed                 |
| d-sorbitol                            | LD50 = 15900 mg/kg (Rat) | Not listed                  | Not listed                 |
| human serum albumin                   | Not listed               | Not listed                  | Not listed                 |

### Repeat dose toxicity:

|                              |                                              |
|------------------------------|----------------------------------------------|
| <b>Species:</b>              | Rat                                          |
| <b>NOAEL:</b>                | 10 <sup>7</sup> PFU                          |
| <b>Administration route:</b> | SC                                           |
| <b>Exposure time:</b>        | 12 weeks                                     |
| <b>Remarks:</b>              | no significant adverse effects were reported |

Replimune documentation is considered proprietary and is made available for business operations and review by employees of Replimune and regulatory agencies. Distribution to third parties without written permission is prohibited.



|                       |                   |
|-----------------------|-------------------|
| <b>Document No.</b>   | 1175-0001 Rev. 03 |
| <b>Effective Date</b> | 14 Jul 2025       |
| <b>Page No.</b>       | 6 of 7            |

|                        |                             |
|------------------------|-----------------------------|
| <b>Document Title:</b> | TUDRIQEV™ Safety Data Sheet |
|------------------------|-----------------------------|

**Species:** Rat  
**NOAEL:** 10<sup>6</sup> PFU  
**Administration route:** SC  
**Exposure time:** 6 months  
**Remarks:** No significant adverse effects were reported

#### Development effects:

**Species:** Rat  
**NOAEL:** 10<sup>6</sup> PFU/rat  
**Administration route:** IV  
**Exposure time:** Gestation days 4, 7, 10, 13, and 16  
**Remarks:** No significant adverse effects were reported.  
No evidence of placental transfer was found.

#### Carcinogen status:

None of the components of this formulation are listed as a carcinogen by IARC NTP or OSHA.

### SECTION XII – ECOLOGICAL INFORMATION

**Ecotoxicity:** Do not empty into drains.  
**Persistence and degradability:** Persistence is unlikely based on information available.  
**Bioaccumulative potential:** No data available.  
**Mobility in soil:** No data available.  
**Other adverse effects:** No data available.

### SECTION XIII – DISPOSAL CONSIDERATIONS

**Waste disposal recommendations:** Dispose of material in accordance with local, State and Federal waste disposal regulations. Decontaminate before disposal with steam sterilization, chemical disinfection, or incineration.

Replimune documentation is considered proprietary and is made available for business operations and review by employees of Replimune and regulatory agencies. Distribution to third parties without written permission is prohibited.



|                       |                   |
|-----------------------|-------------------|
| <b>Document No.</b>   | 1175-0001 Rev. 03 |
| <b>Effective Date</b> | 14 Jul 2025       |
| <b>Page No.</b>       | 7 of 7            |

|                        |                             |
|------------------------|-----------------------------|
| <b>Document Title:</b> | TUDRIQEV™ Safety Data Sheet |
|------------------------|-----------------------------|

#### SECTION XIV – TRANSPORT INFORMATION

|                                |                                                                                                                                                                                                                                                  |
|--------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>UN number</b>               | UN3245 (UN1845 if shipping samples in dry ice)                                                                                                                                                                                                   |
| <b>UN proper shipping name</b> | Genetically Modified Organisms (GMO)                                                                                                                                                                                                             |
| <b>Hazard Class</b>            | 9                                                                                                                                                                                                                                                |
| <b>Packing group</b>           | Products manufactured and packaged in accordance with the requirements of appropriate national authorities and transported for personal health care by medical professionals or individuals are not subject to IATA Dangerous Goods Regulations. |
| <b>Environmental hazards</b>   | No data available.                                                                                                                                                                                                                               |
| <b>Special precautions</b>     | Maintain temperature at -70°C to -90°C (-94°F to -130°F).                                                                                                                                                                                        |

#### SECTION XV – REGULATORY INFORMATION

#### SECTION XVI – OTHER INFORMATION

| <b>Version</b> | <b>Effective date</b> | <b>Description of Changes / Reason for Change</b>           |
|----------------|-----------------------|-------------------------------------------------------------|
| 03             | Xx Jul 2025           | Revision for commercial product; aligned with SDS standards |
| 02             | 30 Jan 2017           | Administrative changes, new header and footer               |
| 01             | 24 May 2016           | New                                                         |

Replimune documentation is considered proprietary and is made available for business operations and review by employees of Replimune and regulatory agencies. Distribution to third parties without written permission is prohibited.